Posters

A case series of combined 0.7mg intravitreal dexamethasone implant (Ozurdex®) and cataract surgery in adult patients with chronic uveitis

Poster Details

First Author: C.Putri UK

Co Author(s):    F. Quhill                    

Abstract Details

Purpose:

In the UK, 0.7mg intravitreal dexamethasone implant (Ozurdex®) is approved by National Institute for Health and Care Excellence for treatment of non-infectious uveitis in pseudophakic eyes. In published literature, 0.7mg intravitreal dexamethasone implant (Ozurdex®) can be implanted intraoperatively following uneventful intraocular lens insertion. This case series assesses the efficacy and safety of intraoperative 0.7mg intravitreal dexamethasone implant (Ozurdex®) in adult patients with chronic uveitis undergoing uncomplicated cataract surgery.

Setting:

Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, UK

Methods:

This is a retrospective case series involving patients with chronic uveitis who underwent combined 0.7mg intravitreal dexamethasone implant (Ozurdex®) and uncomplicated cataract surgery. Average gain in best recorded visual acuity (BRVA) and reduction in central subfield foveal thickness (CSFT) in first 3 months post operation as well as additional treatment with laser, intravitreal steroid or anti-VEGF within 6 months post operation were evaluated. Any ocular complications including raise in intraocular pressure (IOP) were recorded. Last Observation Carried Forward (LOCF) imputation method was used for missing data.

Results:

5 patients with idiopathic retinal vasculitis and chronic uveitis were included. All patients were using systemic immunomodulating agents at the time of surgery. Mean BRVA gain was 14 letters (p=0.006), 21 letters (p=0.191) and 19 letters (p=0.188) at month 1,2 and 3 post-operation respectively. Mean CSFT reduction was 115 microns (p=0.208), 148 microns (p=0.222) and 143 microns (p=0.246) at month 1,2 and 3 post-operation respectively. One patient required an additional intravitreal steroid within 6 months post operation. One patient developed secondary glaucoma, requiring trabectome surgery.

Conclusions:

Intraoperative 0.7mg intravitreal dexamethasone implant (Ozurdex®) is a viable option in managing inflammation up to 3 months post-operatively and reducing the burden of additional treatment up to 6 months post-operatively following uncomplicated cataract surgery in adult patients with chronic uveitis. Careful patient selection and regular IOP monitoring are essential in preventing complications such as secondary glaucoma.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a competing company, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a competing company